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Background: Cardiac steatosis and apoptosis are key processes in diabetic cardiomyopathy, but the underlying
mechanisms have not been elucidated, leading to a lack of effective therapy. The mineralocorticoid receptor
blocker, eplerenone, has demonstrated anti-fibrotic actions in the diabetic heart. However, its effects on the
fatty-acid accumulation and apoptotic responses have not been revealed.
Methods: Non-hypertensive Zucker Diabetic Fatty (ZDF) rats received eplerenone (25 mg/kg) or vehicle. Zucker
Lean (ZL) rats were used as control (n = 10, each group). After 16 weeks, cardiac structure and function was
examined, and plasma and hearts were isolated for biochemical and histological approaches. Cultured cardiomyocytes
were used for in vitro assays to determine the direct effects of eplerenone on high fatty acid and high glucose
exposed cells.
Results: In contrast to ZL, ZDF rats exhibited hyperglycemia, hyperlipidemia, insulin-resistance, cardiac steatosis
and diastolic dysfunction. The ZDF myocardium also showed increased mitochondrial oxidation and apoptosis.
Importantly, eplerenone mitigated these events without altering hyperglycemia. In cultured cardiomyocytes,
high-concentrations of palmitate stimulated the fatty-acid uptake (in detriment of glucose assimilation), accumulation
of lipid metabolites, mitochondrial dysfunction, and apoptosis. Interestingly, fatty-acid uptake, ceramides formation and
apoptosis were also significantly ameliorated by eplerenone.
Conclusions: By blocking mineralocorticoid receptors, eplerenone may attenuate cardiac steatosis and apoptosis, and
subsequent remodelling and diastolic dysfunction in obese/type-II diabetic rats.
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Type-II diabetes (T2DM) is an increasingly prevalent
worldwide disease. Heart failure in these patients, even in
the absence of vascular disease, is a common asymptomatic
pathology known as diabetic cardiomyopathy (DCM).
DCM is characterized by myocardial steatosis, apoptosis,
and subsequent remodelling fibrosis and hypertrophy
[1]. In addition, diverse comorbidities commonly present* Correspondence: olorenzo@fjd.es
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reproduction in any medium, provided the orin diabetes, such as obesity, may accentuate these
responses. In particular, overweight patients with T2DM
have a significantly higher level of myocardial steatosis
preceding and contributing to the early diastolic dys-
function [2]. The excess of circulating free fatty-acid (FFA)
may result in increased cardiac FFA uptake, inadequate
storage and metabolism, and consequent lipotoxicity by
lipid metabolites such as ceramides and reactive oxygen
species (ROS) [3]. However, the underlying molecular
mechanisms have been poorly investigated, leading to a
lack of a diagnostic method and effective therapy. In this
sense, a pharmacological blockade of mineralocorticoid
receptors (MR) could show potential benefits. MR are
activated with equal affinity by aldosterone and glucocorti-l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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them, aldosterone is a bioactive steroid of the major
cardiovascular regulatory system: the renin-angiotensin-
aldosterone system (RAAS). Local RAAS activation has
been associated with some hallmarks of the DCM,
including fibrosis and apoptosis [5,6]. RAAS blockers
based on angiotensin-II receptor inhibition improved
fibrosis and diastolic dysfunction in asymptomatic dia-
betic patients [1]. However, given the pleiotropic role
of angiotensin-II [7] the downstream RAAS effector
aldosterone may be considered as an alternative target.
In this regard, aldosterone promotes angiotensin-II
actions and fibrosis in the diabetic myocardium by up-
regulation of pro-fibrotic and oxidative mediators [8].
Aldosterone exerts also apoptotic responses mainly by
mitochondrial-dependent mechanisms [9], and these
effects are worsened in hyperlipidemia and obesity
[1,6]. Thus, eplerenone, a specific MR blocker, has
demonstrated anti-fibrotic and anti-apoptotic properties
in left ventricular hypertrophy, hypertension, and myo-
cardial infarction [8,10]. Also, in controlled randomized
clinical trials, eplerenone reduced mortality in patients
with heart failure, independently of hypertension im-
provement and on top of angiotensin-II inhibition [11].
However, eplerenone actions on DCM and its related
molecular mechanisms, particularly in steatosis and
apoptosis, have not been elucidated.
Methods
Animal model
An obese non-hypertensive model of T2DM was used
for this study (see Additional file 1). Zucker Diabetic
Fatty (ZDF) rats lead to obesity and insulin resistance
due to the inherited homozygous leptin receptor mutation
(fa/fa) [12]. At the 14th week, male ZDF rats were
randomized and received eplerenone [25 mg/kg/day]
or vehicle. N = 10, each group. Body weight and systolic
blood pressure were monitored. After 16 weeks of
treatment, blood and perfused hearts were isolated
under anaesthesia. Plasma and renal parameters were
measured in the Biochemistry Department of the Hospital.
Hearts were rinsed, dried and weighted. Some ventricular
slices were embedded in p-formaldehyde (to paraffin
inclusion) or optimal-cutting-temperature (OCT) com-
pound, for histology. Left ventricles were frozen in
liquid-N2 for biochemical experiments. These investi-
gations adhered to the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85–23, revised
1996) and the Ethics Committee of the hospital granted
approval for these experiments.
Cardiac structure and function
Cardiac echocardiography was performed under 1.5%
isoflurane-O2 anaesthesia in all rats before (not shown) andafter the treatment. Both M-mode and two-dimensional
(2D) echocardiograms were obtained using a 12 MHz
ultra-band sector transducer (Doppler). Images were
obtained from the left and right parasternal window in
a supine decubitus position. The following parameters
were measured and calculated from M-mode tracing:
left ventricular (LV) end-diastolic diameter (LVDD), LV
end-systolic diameter (LVSD), ejection fraction (EF),
deceleration time and the ratio of the early (E) to late
(A) ventricular filling velocities. Wall thickness of four
segments [anterior, inter-ventricular-septum (IVS), lateral,
and posterior (LVPW) walls] was evaluated on short
axis 2D images.
Examination of cardiac fibrosis, steatosis, apoptosis and
oxidative stress
Paraffin sections (4 μm) of all myocardia were fixed on
slides and used for histology (see Additional file 1).
Cardiac fibrosis was evaluated by Masson trichrome
(Bio-Optica, Milan, Italy) staining. All forms of fibrosis
(interstitial, perivascular and replacement fibrosis) were
quantified together on ten fields of each myocardium
using the Metamorph software. For neutral triglycerides
and lipids determination, frozen OCT-sections were sliced
(5 μm), immersed in propylene glycol and incubated
in Oil red O (ORO) stain. Slides were transferred
to propylene glycol and nuclear-counterstained with
haematoxylin and mounted. Apoptosis was detected a
TUNEL-based apoptosis detection Kit. The percentage
of TUNEL-positive nuclei relative to total nuclei was
determined in a blinded manner by counting 200-300 cells
on ten randomly chosen fields per coverslip for each
myocardium. Dihydroethidium (DHE; 5 μM, Invitrogen)
was used to quantity cytosolic ROS production in
paraffin-fixed myocardia. The average nuclear fluorescence
intensity was measured in five fields of 50 cells by
Metamorph. MitoSOX Red (5 μM, Invitrogen) was used
to measure mitochondrial ROS production in myocardia.
Paraffin sections were fixed on slides and incubated
with MitoSOX Red (15 min at RT and darkness). Slides
were stained 30′ with 4′,6-diamidino-2-phenylindole
(DAPI), washed and mounted.
Cultured cardiomyocytes
H9c2(2-1) is a permanent myoblast cell line derived from
embryonic BD1X rat heart tissue (ATCC; USA). H9c2
were grown at 37°C in 5% CO2 in Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated
foetal calf serum, 100 IE/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM L-glutamine and 5 mM D-glucose (Sigma).
H9c2 differentiated from mononucleated myoblasts into
myocytes upon overnight reduction of serum concentra-
tion before stimulation. Mouse C2C12 myoblasts (ATCC,
USA) were kindly given by Dr. Konhilas (University of
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with 10% foetal calf serum, 50 U/ml penicillin, and
50 μg/ml streptomycin. Before confluency, the medium
was switched to the differentiation medium containing
DMEM and 2% horse serum. After four additional days,
the differentiated C2C12 cells fuse into myotubes. The
hyperlipidemic or hyperglycemic conditions were mimicked
by incubation with high concentrations of a common
saturated FFA (Na+-palmitate, 16:0, 0.12-0.25 mM, Sigma)
or glucose (D-glucose, 33 mM), respectively, for 12 h
(protein expression) or 6 h (mRNA expression). Palmitate
was previously conjugated with BSA in a 3:1 molar ratio
as published elsewhere [13]. In control cells, BSA was
added as described but in the absence of palmitate. Eplere-
none (1 mM-1 μM) was added 1 h before stimulation.
Glucose uptake
For glucose uptake evaluation, cardiomyocytes were grown
under normal conditions and incubated for 3 hours with
100 μM 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino-2-
deoxyglucose (2-NBDG; Invitrogen) and HF or insulin, as
a positive control. After discharging media and washing
the cells, fluorescence was measured in the cytometer.
ATP determination
Cellular ATP levels were quantified using a luciferase-based
assay. Cardiomyocytes were exposed to HF (+/- eplerenone
pre-treatment), after which, cells were rinsed with PBS
and lysed with ATP-releasing buffer (100 mM KH2PO4,
2 mM EDTA, 1 mM dithiothreitol, and 1% Triton X-100
at pH 7.8). Ten μl of the lysate were taken for protein
determination and another ten μl were used for ATP
quantification using the ATP determination kit (Invitrogen),
according to the manufacturer’s instructions.
Detection of lipid-accumulation, apoptosis/survival and
oxidation in cardiomyocytes
For cell steatosis quantification, after 12 h of stimulation
cells were methanol-fixed and stained with ORO, as it
was in myocardia. Lipid accumulation was semi-quantified
by using Metamorph software on five fields of stimulated
cells of at least three independent assays. Apoptosis was
quantified by flow cytometry of cell DNA content (see
Additional file 1). After stimulations, cells were harvested,
permeabilized and DNA-stained with propidium iodide.
The percentage of apoptotic cells is shown. Cells were
also cultured in chamber slides, stimulated, fixed and
nuclear-stained with DAPI. Condensed, piknotic and
fragmented nuclei of apoptotic cells were identified by
confocal microscopy (see Additional file 1). Cell survival
was achieved with a MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] Cell Growth Assay
Kit, following manufacture’s instructions. MitoSOX Red
was used to quantify mitochondrial ROS production.Cardiomyocytes were fixed on slides and incubated
with MitoSOX Red, as it was in hearts. In addition,
mitochondrial superoxide was evaluated by flow cytometry.
Cells were grown in 10% FBS-DMEM without red phenol
until sub-confluency. After overnight starvation, cells
were stimulated, loaded with MitoSOX Red as it was in
myocardia, and trypsin-detached. Cells were counted in
the cytometer. Red fluorescence was measured at several
intervals of time from confocal images. One mM H2O2
was used as control (data not shown).Lipid quantification
Portions of left ventricle myocardium or ~8×105 stimu-
lated cardiomyocytes were dissolved in were dissolved in
25 μL ethanol/mg or 100 μL ethanol, respectively. One
glass bead (acid-washed, 2 mm, Sigma) was added to
every tube and lipids were then extracted by vigorous
shaking with a TissueLyser LT from Qiagen (Hilden,
Germany) for 5 min, at 50 rpm. Tubes were further
centrifuged at 15,400 g and 15°C for 20 min, and 80 μL
from the supernatant were transferred to Ultra High
Performance Liquid Chromatography-Mass (UHPLC-MS)
spectrometry vials with insert. Quantitative evaluation of
the proportion of lipids was performed by a spectrometer
from Agilent Technologies (Santa Clara, CA, USA),
equipped with a 1290 series LC system and a 6550
iFunnel QTOF MS detector. One μL from each sample was
injected (three times) onto the column, a Zorbax Eclipse
Plus C8, 2.1 × 150 mm; 1.8 μm (Agilent Technologies) kept
at 80°C. Compounds were eluted with an 8 min linear
gradient for the mobile phase at 0.6 mL/min, from 50%
ammonium formate 10 mM (pH 6.5) and 50% Methanol
to 100% Methanol. Conditions, reagents, as well as the
procedure for data processing in order to obtain a list
of abundances of all the lipids of interest are provided
in Additional file 1.Western blot and ELISA
A piece (50 mg) of homogenized ventricle (Bullet Blender,
Cultek) or cell extract were dissolved in cold lysis buffer
(see Additional file 1). Equal amounts of proteins (20-
30 μg) were separated on polyacrylamide gels, transferred
to membranes and probed with primary antibodies.
Secondary HRP-linked antibodies (GE Healthcare) were
used for chemo-luminescence development. A representa-
tive gel of all rats or at least three independent experiments
of cultured cells with the semi-quantification scores (n-fold
vs. GAPDH) are shown. Following manufacture’s guide-
lines, rat endogenous aldosterone and glucocorticoids
ELISA kits (antibodies-online.com) were used for aldoster-
one and glucocorticoids detection in cultured media,
respectively. Plasma insulin was detected using a rat insulin
ELISA kit (Mercodia, Sweden).
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Total RNA was extracted from homogenized ventricle
(50 mg) or cultured cardiomyocytes by dissolving in Trizol
reagent (Invitrogen). Equal amounts of RNA (1 μg) were
reverse-transcripted to obtain the cDNA for multiplex
QPCR with specific probes (see Additional file 1). We
show a quantification (n-fold vs. 18 s) of at least two
QPCRs of all rats or three independent cultured cardio-
myocytes experiments.
Statistical analysis
Data are expressed as mean±standard deviation. Multiple
comparisons were performed by non-parametric Kruskal-
Wallis test followed by a Mann-Whitney test. A two-tailed
p < 0.05 was considered significant.
Results
Reduction of hyperlipidemia by eplerenone in
obese/T2DM rats
After 30 weeks, ZDF rats exhibited high plasma levels of
aldosterone, glucose, insulin and lipid profile (Figure 1A).
Interestingly, 16 weeks of eplerenone substantially trig-
gered plasma aldosterone and reduced plasma lipids. No
significant changes in systolic blood pressure (135.0 ± 8.1
vs. 139.8 ± 15.2 mm Hg for ZL and ZDF rats, respectively)
were observed. Markers of severe renal (urea, blood urea
nitrogen, creatin and albumin) and liver (aspartyl and
alanine aminotransferases) injury remained within the
normal ranges in all groups (not shown). Of note, since
mineralocorticoid antagonists may induce hyperkalemia
[14], we monitored plasma potassium concentrations.
Conveniently, at this dose/time of eplerenone, potassium
was kept within the non-toxic levels in all rats (4.4 ±
0.58 mEq/l).
Attenuation of cardiac hypertrophy and diastolic
dysfunction by eplerenone in ZDF rats
As previously documented [15], at this stage of the disease
ZDF rats exhibited weight loss. However, a significant
elevation of the heart weight/femur length (HW/FL) ratio
was observed (Figure 1A). Moreover, by Echo-Doppler
(Figure 1B), ZDF hearts exhibited an increase of the
inter-ventricular septum (IVS) thickness, and a reduction
of left ventricular diastolic (LVDD) and systolic (LVSD)
diameters, probably related to IVS hypertrophy. In this
sense, the mRNA expression of atrial natriuretic peptide
(ANP), a molecular marker of hypertrophy, was increased
in the left ventricle of ZDF (Figure 1C). Brain natriuretic
peptide (BNP) was, however, not significantly modified
in the rats (not shown). In addition, ZDF showed a
prolongation of the deceleration time and decreased
E/A ratio, suggesting diastolic dysfunction. However,
the ejection fraction (EF) was unchanged. Interestingly,
the altered HW/FL, IVS, ANP expression, decelerationtime and E/A ratio were attenuated by eplerenone
administration.
Eplerenone ameliorated fibrosis and apoptosis in the
ZDF myocardium
Left ventricular myocardium in the ZL rats exhibited a
normal architecture with regular interstitial space. How-
ever, abnormal myocardial architecture (cardiomyocyte
hypertrophy and disarray, and enlarged interstitial space)
was observed in the ZDF group (Additional file 2: Figure
S1A). Confirming previous data in experimental [16]
and human [17] diabetes, the deposition of interstitial
and mainly perivascular extra-cellular matrix (ECM),
and the increase of pro-fibrotic factors such as type-IV
collagen and fibronectin, were attenuated by eplerenone
(Additional file 2: Figure S1A, B). More interestingly, since
both hypertrophy (Figure 1A-C) and fibrosis (Additional
file 2: Figure S1A, B) may contribute to myocardial
remodelling in response to a loss of cells [6,18], we
focused on the apoptotic response of ZDF hearts and
their treatment with eplerenone. By TUNEL (Figure 2A),
we observed an increase of apoptotic-positive nuclei in
ZDF (4.1 vs. 1.2 cells/mm2 ZL), which was reduced by
eplerenone. Moreover, ZDF showed an activation of
pro-apoptotic caspase-3, and eplerenone mitigated this
response (Figure 2B).
Eplerenone decreased apoptosis in high fatty
acid-stimulated cardiomyocytes
To elude the confounding effects of reduced hyperlipid-
emia on the eplerenone-treated ZDF myocardium, we
tested the apoptosis response in eplerenone-pretreated
cultured cardiomyocytes exposed to high concentrations
of a saturated fatty acid (HF) and/or glucose (HG). In
our conditions, HF, but not HG, significantly increased
the number of apoptotic cardiomyocytes as early as 14 h
incubation and at 0.12 mM (Additional file 2: Figure
S1C), similarly to a lethal cytokine (30 U/ml IFNγ; not
shown). In addition, caspase-3 activation and subsequent
nuclear pyknosis and cell loss were detected mainly in
HF-incubated cardiomyocytes (Additional file 2: Figure
S1D). HF and HG co-incubation did not significantly
alter the magnitude of HF-induced apoptosis. In addition,
HF induced the release of aldosterone from cardiomyo-
cytes to the cultured media (Additional file 3: Figure S2),
and thus, eplerenone may block aldosterone-associated
actions on cultured cardiomyocytes. In fact, eplerenone
(1 μM) reduced HF-induced cell apoptosis and caspase-
3 activation (Figure 3A, B). These data were confirmed
by MTT survival assays. Incubation with HF significantly
decreased the cardiomyocytes viability (black bars) and
this effect was mitigated by eplerenone (only for 0.12 mM;
Figure 3C). HG and eplerenone alone did not modify
the survival rates.
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Figure 4 Eplerenone decreased lipid steatosis and ceramides formation in ZDF hearts. (A) Left, FAT/CD36 isoforms (~90 kDa and ~53 kDa;
solid bars and broken bars in the quantification graph, respectively) expression in ZL, ZDF and ZDF+eplerenone hearts. Right, FABP3, ACADl and
ACADm mRNA expression. (B) Detection of intra-cellular lipid deposition (steatosis) in the rats by ORO staining. A detailed 5x magnification of the
lipid droplets is shown in ZDF. (C) Protein levels of GPAT1 (~90 kDa) and DGAT1 (~52 kDa) in rat myocardia. (D) By UHPLC-MS, DAG, phosphatidyl-choline
(PC), TAG, and ketosphingosine, sphingosine and sphinganine levels. *p < 0.05 and **p < 0.01 vs. ZL. †p < 0.05 and ††p < 0.01 vs. ZDF rats.
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Apoptosis in obese/T2DM hearts may result from an
excessive uptake and accumulation of FFA [3,18]. The
main cardiac FFA protein-transporter is FAT/CD36,
which traffic from intracellular stores (endosomes) to
the sarcolemma to facilitate FFA uptake [19]. Indeed,
FAT/CD36 isoforms, likely corresponding to the non-
glycosylated (lower) and glycosylated/phosphorylated
(upper) proteins [20], were increased in the ZDF myo-
cardium (Figure 4A, left). Next, FFA can deliver to
different organelle, primarily to mitochondria for energy
consecution. In this regard, ZDF showed elevated mRNA
expression of a FFA-cytosolic transporter, the FFA-binding
protein-3 (FABP3; Figure 4A, right) and two main β-
oxidation enzymes, ACADl and ACADm (large chain- and
medium chain- acyl-CoA dehydrogenases, respectively)
(Figure 4A, right). However, as a consequence of high
FFA-uptake (or uncoupled FFA-uptake and oxidation), FFA
can be stored by re-esterification as TAG and phospholipids
in the cytosol of obese/T2DM cardiomyocytes [21]. In this
sense, we identified numerous cytosolic lipid droplets
(Figure 4B) in ZDF myocardia, typically from myocardial
steatosis. Also, ZDF up-regulated two rate-limiting
enzymes of lipid re-esterification, GPAT1 (glycerol-3-
phosphate acyltransferase-1) and DGAT1 (DAG acyl-
transferase-1) (Figure 4C), and increased TAG content
(Figure 4D, left). Then, if this accumulation persists overt
time, lipids may diverge to lipotoxic metabolites such as
ceramides [22,23]. In this regard, ZDF hearts accumulated
sphingolipids precursors of ceramides such as ketosphin-
gosine and sphingosine (Figure 4D, right). Interestingly,
eplerenone lessened the expression/translocation of FAT/
CD36 and FABP3, myocardial steatosis, GPAT1/DGAT1,
and ceramides intermediates (Figure 4A-D).
Eplerenone decrease lipid metabolism and accumulation
in HF-stimulated cardiomyocytes
Cardiac steatosis was confirmed in HF-incubated cardio-
myocytes by Oil Red-O staining (Figure 5A). However,
previous data had suggested that H9c2 cells might not
express FAT/CD36 receptor [24]. Thus, we used another
cell line of myocytes with demonstrated FAT/CD36
expression and activated lipid metabolism [25]. C2C12 cells
increased also lipid droplets (not shown), and up-regulated
glycosylated/phosphorylated FAT/CD36 isoforms after
HF incubation, possibly corresponding to its sarco-
lemma translocation (Figure 5B). Downstream, FABP3and ACADl/ACADm transcripts were augmented by
HF (Figure 5C). GPAT1/DGAT1 (Figure 5D, top), DAG,
phospholipids (phosphatidyl-choline) and sphingosine
were also increased (Figure 5D, bottom). However, in
agreement with ZDF-treated rats, eplerenone mitigated
cytosolic lipid accumulation, FAT/CD36 and FABP3
after HF (Figure 5A-C). Eplerenone reduced also DGAT1
and sphingosine (Figure 5D). These data suggest a direct
effect of eplerenone on lipid uptake and storage at the
myocardium.
By other hand, unsurprisingly, HG did not induce
steatosis in cardiomyocytes (not shown). However, the
stimulated lipid storage and metabolism could affect
glucose utilization [21]. In this sense, as soon as 3 h of HF-
incubation, C2C12 exhibited a significant decrease of
glucose uptake that was reverted by eplerenone (Figure 5E).Eplerenone improved DCM-associated mitochondrial
stress but not mitochondrial regulators
Apoptosis in the obese/T2DM heart has been also
related to an overproduction of reactive oxygen species
(ROS), which damages cell mitochondria and induce
apoptosis [3]. In our model, ZDF showed an increase of
cytosolic (Figure 6A, left) and mainly mitochondrial
(Figure 6A, right) superoxide production, but eplerenone
attenuated these levels. These data were confirmed in
cultured cardiomyocytes. By flow cytometry (Figure 6B,
left) and immunofluorescence (Figure 6B, right), HF
induced mitochondrial-ROS formation as early as 10 min
of stimulation, and eplerenone prevented this effect.
Consistently, mitochondrial ATP production was decreased
in HF-incubated cardiomyocytes (0.25 mM), and restored
after eplerenone treatment (Figure 6C).
More interestingly, the levels of key regulators of
mitochondrial function such as the complex peroxi-
some proliferator activated receptor-α (PPARα)/PPARγ
coactivator-1α (PGC1α), and related transcription factors
involved in mitochondrial biogenesis and oxidative
metabolism, such as the mitochondrial transcription
factor-A (Tfam) and the nuclear respiratory factor-1
(NRF1) [26], were significantly reduced in ZDF hearts
(Figure 7A-B). However, only PPARα ωασ restored by
eplerenone. Interestingly, HF (0.25 mM) did not alter
PPARα/PGC1a (not shown), but reduced the content
of Tfam and NRF1 in H9c2. Again, eplerenone could
not prevent these responses (Figure 7C).
AD
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E
Figure 5 (See legend on next page.)
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Figure 5 Eplerenone reduced lipid metabolism and ceramides formation in cultured cardiomyocytes. (A) Lipid accumulation in control,
HF- and HF+eplerenone-treated H9c2. (B) FAT/CD36 protein content in C2C12 myotubes (~90 kDa and ~53 kDa; solid bars and broken bars in
the quantification graph, respectively). (C) FABP3, ACADl and ACADm transcript levels. (D) Top, GPAT1 and DGAT1 protein expression. Bottom,
DAG, PC, TAG, and ketosphingosine, sphingosine and sphinganine levels by UHPLC-MS. (E) Eplerenone improved glucose assimilation in
HF-incubated C2C12. Eplerenone was pre-administrated in some HF- or insulin-stimulated cells, and 2-NBDG was evaluated. *p < 0.05 and
**p < 0.01 vs. related control. †p < 0.05 and ††p < 0.01 vs. related HF.
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Elevated content of lipids in cardiac muscle, and following
increase of apoptosis and ECM deposition are distinctive
of human and experimental DCM. These abnormalities
may generate cardiac hypertrophy and dysfunction, even-
tually leading to congestive heart failure [1,21]. Chronic
obese/T2DM rats exhibited cardiac steatosis, apoptosis,
fibrosis and hypertrophy, and diastolic (but not systolic)
dysfunction. In DCM, diastolic dysfunction is not
necessary accompanied with a reduction of EF [12,27], or
it occurs earlier than systolic alteration [28]. Nevertheless,
a valid treatment for DCM patients is needed. As we
confirmed here, the blockade of MR has emerged as an
effective anti-fibrotic therapy in DCM [5,29]. However,
we also claim it might induce anti-steatosis and anti-
apoptosis actions, contributing to the recovery of diastolic
function [2].
Long-term hyperglycemia promotes negative effects
on the heart, affecting the cardiac expression of lipid-,
glucose- and ketone bodies-metabolic, signalling and
stress-response genes [30,31]. Chronic hyperglycemia is
related with cardiac fibrosis, coronary disease and in-
creased risk of heart attack, and it has been also associated
with higher levels of toxic glycolytic intermediates and
troponin-T, a blood marker for heart damage [32].
However, recent clinical trials have revealed non-significant
advances of intensive glycemic control on the mortality of
DCM patients with cardiovascular events [33], suggesting
that other events such as lipotoxicity may be targeted
for new therapies. In this sense, eplerenone reduced
hyperlipidemia without altering hyperglycemia in ZDF
rats (Figure 8). Similar data were found in obese/T2DM
mice [34], and individuals with essential hypertension
[35]. Thus, the anti-hyperlipidemic actions of eplerenone
could be independent of changes in glycemia or blood
pressure [36], and possibly due in part to an improvement
of insulin resistance. After MR blockade, experimental
and clinical studies have demonstrated an increase of
the insulin response by reduction of redox-sensitive
and -insensitive serine kinases, and consequent activation
of IRS-1 signaling. Also, the MR blockade increased both
insulin and glucose receptor genes, leading to improved
glucose uptake [37] [38]. Here we also showed a restor-
ation of IRS-1 levels (Additional file 3: Figure S2B) and
glucose uptake in eplerenone-treated ZDF or HF-exposed
cardiomyocytes, respectively. Nevertheless, the role ofeplerenone on lipid intestinal absorption and release from
adipose tissue is not clarified. In this sense, eplerenone
prevented adiponectin reduction and leptin elevation of
adipose tissue in obese/T2DM mice [34].
The attenuated plasma lipid availability could bring
about a reduction of lipid deposition within the heart.
However, we found potential direct anti-steatotic effects in
DCM (Figure 8). The expression/sarcolemma relocation
of FAT/CD36 (and FABP3) was ameliorated with epler-
enone in ZDF hearts, but also in HF-incubated cardio-
myocytes. Interestingly, FAT/CD36, FABP3, and several
β-oxidation enzymes, are transcriptional targets of PPARα
[39], however, PPARα was elevated after eplerenone in
ZDF hearts. The metabolic changes associated to the
activity of PPARα may depend on the stage of obesity
and diabetes [40,41]. Chronic exposure to elevated FFA
reduced PPARα in cardiomyocytes, and this effect was
proposed to further decrease cardiac function and increase
intracellular fat stores [21]. Also, the PPAR-response
elements were not identified on FAT/CD36 gene [42],
and PPARα may need specific coactivators such as
PGC1α to mediate these actions [43]. Of interest, PGC1α
was also not stimulated in ZDF. Next, we observed an
increase of cytosolic lipid droplets and activation of lipid
re-esterification in ZDF myocardia and HF-incubated
cardiomyocytes (Figure 8). This effect may be related to
the rise of TAG, and DAG and PC, respectively. Moreover,
we detected an accumulation of sphingosine in both ZDF
myocardia and HF-exposed cells. The increased lipogenic
capacity [21,44], and overall, the cardiac deposition of
ceramides could promote insulin resistance, lipoapoptosis
and dysfunction in the ZDF heart [22,23]. However,
eplerenone reduced lipid droplets, lipid re-esterification
enzymes and ceramides formation, likely contributing
to the improved diastolic dysfunction (Figure 8).
Finally, a lipid overload together with a reduction in
glucose assimilation may also result in non-neutralized
mitochondrial ROS production and apoptosis in DCM
(our data and [41]). In ZDF myocardia and HF-exposed
cardiomyocytes we have described an increase of cyto-
solic and mainly mitochondrial ROS, consequent ATP
deficiency, and apoptosis. These levels correlated with
the reduced expression of PPARα/PGC1α complex and
linked transcription factors (Tfam and NRF1). Interestingly,
eplerenone attenuated ROS levels, ATP deficiency and
apoptosis, without altering these mitochondrial regulators,
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Figure 7 Mitochondrial-related factors in ZDF myocardia and HF-incubated cardiomyocytes. (A) PPARα (~50 kDa), PGC1α (~120 kDa), and
(B) Tfam (~25 kDa) and NRF1 (~55 kDa) levels in the ZDF model. (C) Tfam and NRF1 protein content in 12 h HF-stimulated cardiomyocytes.
*p < 0.05 and **p < 0.01 vs. control. †p < 0.05 vs. related ZDF or HF.
(See figure on previous page.)
Figure 6 Anti-oxidant effects of eplerenone in ZDF hearts and HF-stimulated cardiomyocytes. (A) DHE and Mitosox staining (red) in
ZDF and ZDF-treated myocardia. Nuclear labelling by DAPI (blue) is also shown. N = 6, each group. (B) By flow cytometry (left), mitosox staining
in 0-60 min HF and HF+eplerenone (10-6 M) incubated cardiomyocytes. By immunofluorescence (right), mitosox staining after 10 min of HF
stimulation (0.12 mM). (C) ATP production in 12 h HF-stimulated cardiomyocytes. *p < 0.05 and **p < 0.01 vs. control. †p < 0.05 and ††p < 0.01
vs. related ZDF or HF.
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Figure 8 Potential protective effects of eplerenone in chronic obese/T2DM hearts. In cardiomyocytes, plasma lipids can be uptake as FFA
to undergo mitochondrial β-oxidation for energy supply. An overload of FFA causes increased oxidation and ROS, mitochondrial damage and
apoptosis. FFA may also accumulate as TAG and phospholipids (PL) in lipid droplets, or deviate to ceramides. However, PPARα activation may be
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lessening. Eplerenone decreased also β-oxidation in
HF-incubated cells, as a source of ROS. Additionally,
previous works also demonstrated protective properties
of eplerenone in hyperosmotic cardiomyocytes [45],
and some pro-apoptotic and pro-inflammatory/oxida-
tive factors may be involved [46,47]. Altogether, by MR
blockade and steatosis reduction, eplerenone could de-
crease aldosterone- and FFA-associated pro-oxidative,
apoptotic and fibrotic actions [34] (Figure 8). Further
investigations focusing on these particular mechanisms
will add new insights to the knowledge of eplerenone
protection in DCM. However, long-term eplerenoneadministration could lead to hyperkalemia, resulting in
depolarization of the membrane potentials of cardiac
cells and fatal arrhythmias [14]. Also eplerenone may
induce off-target effects through the aldosterone com-
petitive antagonism of the androgen receptor, affecting
hormone secretion and function [48].
Study limitations
Glucocorticoids were detected in cultured media (Additional
file 3: Figure S2A). In particular, plasma cortisol was ~30%
higher in ZDF than in ZL rats. Since glucocorticoids
can also bind to MR, we cannot exclude their potential
effects in hearts and cardiomyocytes. In addition, the
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formation since the decreased plasma FFA/TAG levels
after eplerenone may be caused by differences in food
consumption. Nevertheless, previous data in rat dem-
onstrated no variation in food and water consumption
after eplerenone administration [49].
Conclusions
Intracellular accumulation of lipids in the experimental
obese/T2DM heart appears to play an important role in
the pathogenesis of DCM. However, eplerenone decreased
hyperlipidemia, myocardial FFA-uptake and steatosis,
insulin resistance, and ceramides and ROS accumulation,
which all may contribute to the improvement of energy
consecution, cardiac remodelling and function. Even in
the presence of high glucose concentration, our work
supports the importance of controlling myocardial lipo-
toxicity for preventing the development of DCM, and
eplerenone could attend as a valid therapy.
Additional files
Additional file 1: Supplemental Material. Details of the ZDF model
and used techniques.
Additional file 2: Figure S1. Eplerenone attenuated fibrosis and ECM
proteins in the ZDF myocardium. (A) By Masson, detection of ECM
deposition (blue-green) in ZDF and ZDF+eplerenone hearts (top). (B)
Type-IV collagen and fibronectin mRNA expression in the rats. N = 6, each
group. (C) HF induced apoptosis in cultured cardiomyocytes. Cardiomyocytes
were stimulated with HF (0.12-0.5 mM) or glucose (HG, 25-33 mM) for 3-24 h,
and apoptosis was quantified by flow cytometry. The percentage of
apoptotic cells (sub G0/G1 cell cycle phase) is represented. (D) Caspase-3
activation after 3-14 h of HF and/or HG incubation, and nuclei piknosis
(detailed in a bright field) and cell loss in 14 h-stimulated cardiomyocytes.
*p < 0.05 and **p < 0.01 vs. related control. †p < 0.05 and ††p < 0.01 vs.
ZDF rats.
Additional file 3: Figure S2. (A) Aldosterone and glucocorticoids
release from cardiomyocytes. Aldosterone and glucocorticoids (GC)
were measured in cultured media after 12 h HF and HF+eplerenone
incubations. (B) Cardiac IRS-1 expression. Total IRS-1 levels (~130 kDa)
were detected in rat myocardia. *p < 0.05 vs. related control. ††p < 0.01
vs. ZDF rats.
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